These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
284 related items for PubMed ID: 26801902
1. Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines. Jandu H, Aluzaite K, Fogh L, Thrane SW, Noer JB, Proszek J, Do KN, Hansen SN, Damsgaard B, Nielsen SL, Stougaard M, Knudsen BR, Moreira J, Hamerlik P, Gajjar M, Smid M, Martens J, Foekens J, Pommier Y, Brünner N, Schrohl AS, Stenvang J. BMC Cancer; 2016 Jan 22; 16():34. PubMed ID: 26801902 [Abstract] [Full Text] [Related]
2. Transcriptional targeting of human liver carboxylesterase (hCE1m6) and simultaneous expression of anti-BCRP shRNA enhances sensitivity of breast cancer cells to CPT-11. Mishra MN, Vangara KK, Palakurthi S. Anticancer Res; 2014 Nov 22; 34(11):6345-51. PubMed ID: 25368234 [Abstract] [Full Text] [Related]
3. Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations. Jensen NF, Agama K, Roy A, Smith DH, Pfister TD, Rømer MU, Zhang HL, Doroshow JH, Knudsen BR, Stenvang J, Brünner N, Pommier Y. J Exp Clin Cancer Res; 2016 Mar 31; 35():56. PubMed ID: 27029323 [Abstract] [Full Text] [Related]
4. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. Nakamura Y, Oka M, Soda H, Shiozawa K, Yoshikawa M, Itoh A, Ikegami Y, Tsurutani J, Nakatomi K, Kitazaki T, Doi S, Yoshida H, Kohno S. Cancer Res; 2005 Feb 15; 65(4):1541-6. PubMed ID: 15735043 [Abstract] [Full Text] [Related]
5. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. Robey RW, Medina-Pérez WY, Nishiyama K, Lahusen T, Miyake K, Litman T, Senderowicz AM, Ross DD, Bates SE. Clin Cancer Res; 2001 Jan 15; 7(1):145-52. PubMed ID: 11205902 [Abstract] [Full Text] [Related]
6. Expression and functional analyses of breast cancer resistance protein in lung cancer. Kawabata S, Oka M, Soda H, Shiozawa K, Nakatomi K, Tsurutani J, Nakamura Y, Doi S, Kitazaki T, Sugahara K, Yamada Y, Kamihira S, Kohno S. Clin Cancer Res; 2003 Aug 01; 9(8):3052-7. PubMed ID: 12912956 [Abstract] [Full Text] [Related]
7. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic. Shiozawa K, Oka M, Soda H, Yoshikawa M, Ikegami Y, Tsurutani J, Nakatomi K, Nakamura Y, Doi S, Kitazaki T, Mizuta Y, Murase K, Yoshida H, Ross DD, Kohno S. Int J Cancer; 2004 Jan 01; 108(1):146-51. PubMed ID: 14618629 [Abstract] [Full Text] [Related]
8. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2). Jiao X, Zhao L, Ma M, Bai X, He M, Yan Y, Wang Y, Chen Q, Zhao X, Zhou M, Cui Z, Zheng Z, Wang E, Wei M. Breast Cancer Res Treat; 2013 Jun 01; 139(3):717-30. PubMed ID: 23780685 [Abstract] [Full Text] [Related]
10. Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells. Zhang Y, Wang H, Wei L, Li G, Yu J, Gao Y, Gao P, Zhang X, Wei F, Yin D, Zhou G. Breast Cancer Res Treat; 2010 Oct 01; 123(3):679-89. PubMed ID: 19967559 [Abstract] [Full Text] [Related]
11. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Doyle L, Ross DD. Oncogene; 2003 Oct 20; 22(47):7340-58. PubMed ID: 14576842 [Abstract] [Full Text] [Related]
17. BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells. Yang CH, Schneider E, Kuo ML, Volk EL, Rocchi E, Chen YC. Biochem Pharmacol; 2000 Sep 15; 60(6):831-7. PubMed ID: 10930538 [Abstract] [Full Text] [Related]
18. Transcriptional upregulation of breast cancer resistance protein by 17beta-estradiol in ERalpha-positive MCF-7 breast cancer cells. Zhang Y, Zhou G, Wang H, Zhang X, Wei F, Cai Y, Yin D. Oncology; 2006 Sep 15; 71(5-6):446-55. PubMed ID: 17878748 [Abstract] [Full Text] [Related]
19. Combining ABCG2 Inhibitors with IMMU-132, an Anti-Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers. Chang CH, Wang Y, Zalath M, Liu D, Cardillo TM, Goldenberg DM. Mol Cancer Ther; 2016 Aug 15; 15(8):1910-9. PubMed ID: 27207776 [Abstract] [Full Text] [Related]